TITLE

Dispute over Vioxx study plays out in New England journal

AUTHOR(S)
Kondro, Wayne
PUB. DATE
May 2006
SOURCE
CMAJ: Canadian Medical Association Journal;5/9/2006, Vol. 174 Issue 10, p1397
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the controversy regarding a Canadian-led study of the anti-arthritis drug rofecoxib (Vioxx) published by the "New England Journal of Medicine" in November 2000. Accusation of the journal that the study contained misleading conclusions regarding the drug's safety; Response of the authors of the study to the accusation; Demand of the journal for a correction to the study.
ACCESSION #
21062623

 

Related Articles

  • Case Report: Safety and Efficacy of Tocilizumab in a Patient with Rheumatoid Arthritis and Chronic Hepatitis C. Iebba, Filippo; Di Sora, Fiorella; Tarasi, Agapito; Leti, Wilma; Montella, Tatiana; Montella, Francesco // Case Reports in Medicine;2012, p1 

    Tocilizumab is a monoclonal humanized anti-IL-6-receptor antibody used for the treatment of rheumatoid arthritis. The safety of tocilizumab in HCV patients is an open question. We report on safety and efficacy of tocilizumab in a 71-year-old female with rheumatoid arthritis and chronic hepatitis...

  • Get a grip on joint pain. Dolby, Victoria // Better Nutrition;Mar99, Vol. 61 Issue 3, p50 

    Focuses on nutritional arthritis therapy. Glucosamine sulfte and chondroitin sulfate; Methylsulfonylmethane; Essential fatty acids; Cayenne peppers.

  • An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada. Zabinski, R.A.; Burke, T.A.; Johnson, J.; Lavoie, F.; Fitzsimon, C.; Tretiak, R.; Chancellor, J.V.M. // PharmacoEconomics;Aug2001 Supplement 1, Vol. 19 Issue 8, p49 

    Objective: To construct a decision analytical model to compare the costs and clinical consequences of treating patients with celecoxib or various nonsteroidal anti-inflammatory drug (NSAID)/gastrointestinal (GI) co-therapy regimens for the management of osteoarthritis and rheumatoid arthritis....

  • LETTERS. Lau, Ruth; Morey, Diane; Jacobson, Richard; Williston, Bethany; Brown, Glen; Katz, Robert; Carver, Bruce; Regulinski, Thad L. D.; Harrison, Cathie; Dahlbeck, Lennart; Oteri, Paul Onoriode; Awofeso, Pelu; Tee, Tan Boon; Carroll, Peter // Time International (South Pacific Edition);11/1/2004, Issue 43, p6 

    Several letters to the editor are presented in response to articles published in the October 11, 2004 issue including "What do Women Want," an article on the prescription drug Vioxx's withdrawal from the market and an article on fashion designer Geoffrey Beene.

  • Economic Evaluation of Celecoxib, a New Cyclo-Oxygenase 2 Specific Inhibitor, in Switzerland. Chancellor, J.V.M.; Hunsche, E.; de Cruz, E.; Sarasin, F.P. // PharmacoEconomics;Aug2001 Supplement 1, Vol. 19 Issue 8, p59 

    Objective: The aim of this study was to predict the cost effectiveness of celecoxib, a cyclo-oxygenase 2 (COX-2) specific inhibitor, in the treatment of arthritis patients in Switzerland. Methods: We applied a decision analytical model to compare the effects of 6 months' treatment with the...

  • A Framework for Evaluating the Clinical Consequences of Initial Therapy with NSAIDs, NSAIDs plus Gastroprotective Agents, or Celecoxib in the Treatment of Arthritis. Burke, T.A.; Zabinski, R.A.; Pettitt, D.; Maniadakis, N.; Maurath, C.J.; Goldstein, J.L. // PharmacoEconomics;Aug2001 Supplement 1, Vol. 19 Issue 8, p33 

    Objective: The purpose of this study is to provide a framework for estimating the economic efficiency of nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), concomitant gastroprotective agents (GPAs) to reduce the risk of NSAID toxicity, and celecoxib, a specific cyclo-oxygenase-2...

  • Vioxx study adds fire to arthritis drug battle.  // Drug Store News;7/19/99, Vol. 21 Issue 11, pCP13 

    Focuses on the result of a study on the effectivity of Vioxx, an anti-arthritis drug conducted by Merck company. Comparison of Vioxx with the drug Celebrex; Reaction from Monsanto and Pfizer on the study findings of Merck; Comments from Philip Needleman, co-president of Searle.

  • Arthritis treatment options.  // Executive Health's Good Health Report;Nov97, Vol. 34 Issue 2, p1 

    Part II. Evaluates treatment modalities for arthritis. Includes chemotherapy, diet and exercise therapy; Common antiarthritic drugs used; Includes use of non steroidal anti-inflammatory drugs (NSAID), analgesics and synthetic prostaglandins; Mechanism of action; Side effects; Recommended diet;...

  • Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. Neumann, V.C.; Grindulis, K.A.; Hubball, S.; McConkey, B.; Wright, V. // British Medical Journal (Clinical Research Edition);10/15/1983, Vol. 287 Issue 6399, p1099 

    Compares the efficacy of penicillamine and sulphasalazine in treating rheumatoid arthritis. Capabilities of Sulphasalazine in producing remissions; Precautions on the intake of the drugs; Concerns on the side effects of penicillamine.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics